ZFHX3 variants cause partial epilepsy of childhood and spasms with favorable outcomes

Ming-Feng He[1,†], Li-Hong Liu[1,†], Sheng Luo[1,†], Juan Wang[1], Jia-Jun Guo[1], Peng-Yu Wang[1], Qiong-Xiang Zhai[2], Su-Li He[3], Dong-Fang Zou[4], Xiao-Rong Liu[1], Bing-Mei Li[1], Hai-Yan Ma[5], Jing-Da Qiao[1], Peng Zhou[1], Na He[1,*], Yong-Hong Yi[1,*], and Wei-Ping Liao[1]

For the China Epilepsy Gene 1.0 Project

1. Department of Neurology, Institute of Neuroscience, Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province and the Ministry of Education of China, the Second Affiliated Hospital, Guangzhou Medical University, Guangzhou 510260, China.

2. Department of Pediatrics, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510120, China.

3. Department of Pediatrics, Shantou Chaonan Minsheng Hospital, Shantou 515000, China.

4. Epilepsy Center and Department of Neurology, Shenzhen Children's Hospital, Shenzhen 518029, China.

5. Department of Functional Neurosurgery, Affiliated Nanjing Brain Hospital of Nanjing Medical University, Nanjing 210029, China.

[*]Correspondence Authors:

Prof. Yong-Hong Yi

E-mail: yyh168@sina.com

Tel: +86-18926298172

Institute of Neuroscience and Department of Neurology of the Second Affiliated Hospital of Guangzhou Medical University, Chang-Gang-Dong Road 250, Guangzhou, 510260, China

Dr. Na He

E-mail: henachilli@163.com

Institute of Neuroscience and Department of Neurology of the Second Affiliated Hospital of Guangzhou Medical University, Chang-Gang-Dong Road 250, Guangzhou, 510260, China

†These authors contributed equally to this work and share co-first authorship.

Abstract

Background and Objectives: The *ZFHX3* gene is highly expressed in the developing brain and plays vital roles in embryonic development, cell proliferation, neuronal differentiation, and neuronal death. The association between the *ZFHX3* gene and human disease was not defined.

Methods: Whole-exome sequencing was performed in a cohort of 378 patients with partial (focal) epilepsy of childhood. A *Drosophila Zfh2* knockdown model was used to validate the association between *ZFHX3* and epilepsy. The expression profile of the *ZFHX3* ortholog was assessed by RT-qPCR and the data from the Brainspan database.

Results: Eight pairs of compound heterozygous variants in *ZFHX3* were identified in eight unrelated cases with partial epilepsies. The identified *ZFXH3* variants had low or no frequencies in the populations of gnomAD. The *ZFHX3* gene presented significantly higher excesses of variants in the case cohort, including a higher excess of biallelic variants than the expected number of East Asian populations, higher aggregated frequencies than that in gnomAD, and a higher frequency of compound heterozygous variants than that in the asymptomatic parent controls. In *Zfh2* knockdown flies, the incidence and duration of seizure-like behavior were significantly higher than those of the controls. The *Zfh2* knockdown flies exhibited more firing in excitatory neurons than the wild-type line in electrophysiological recordings. All patients with *ZFHX3* compound heterozygous variants presented focal seizures and focal discharges on EEGs. One patient experienced frequent

nonconvulsive status epilepticus, and two patients evolved from early spasms; the three cases also had neurodevelopmental abnormalities. However, all patients achieved seizure-free. In *Drosophila*, the expression of *Zfh2* is high in larvae and decreased in pupae and early adults. In mice, *Zfhx3* is predominantly expressed in fetuses and decreases dramatically after birth. In humans, the data from the Brainspan database showed that *ZFHX3* is highly expressed in the embryonic period and decreased after birth.

Conclusion: This study suggested that *ZFHX3* is potentially a novel causative gene of partial epilepsy of childhood and infantile spasms. The correlation between the outcome and gene expression stage provided insight into the underlying mechanism of the natural course of illness, potentially being helpful in the management of the patients.

Keywords: *ZFHX3* gene, partial epilepsy, trio-based WES, neurodevelopmental disorder, gene expression stage

Glossary

WES = whole-exome sequencing; AEDs = antiepileptic drugs; EEG = electroencephalography; MRI = magnetic resonance imaging; sEPSP = spontaneous excitatory postsynaptic potential; GDS = gene-dependent (expression) stage; *ZFHX3* = zinc finger homeobox 3 gene; pLI = probability of being LOF intolerant; LOEUF = LOF observed/expected upper bound fraction; pHaplo = probability of haploinsufficiency.

Introduction

Epilepsy is a common neurological disorder with age-dependent seizures. In children, the prevalence of epilepsy ranges from 0.5% to 1%,[1] and approximately 68% of childhood patients present focal seizures.[2] Epilepsy affects approximately 0.7% of infants,[3] and approximately 10% of infantile patients with epilepsy present spasms.[4] Genetic factors are believed to be the main cause of epilepsy, accounting for approximately eighty percent of the cases.[5] Previously, a number of causative genes were identified in children with partial (focal) epilepsy, such as *DEPDC5*[6], *GRIN2A*[7], *UNC13B*[8], *HCFC1*[9], *LAMA5*[10], *BCOR*[11], *CELSR1*[12], *BRWD3*[13], *FAT1*[14], and *ELP4*[15]. The genes associated with infantile spasms include *KCNQ2*[16], *KCNT1*[17], *GRIN2B*[18], *STXBP1*[19], *TBC1D24*[20], *SCN1A*[21], *CDKL5*[22], and *ARX*[23]. However, the etiology in most patients with childhood partial epilepsy and/or infantile spasms remains to be elucidated.

In this study, we conducted trio-based whole-exome sequencing (WES) in a cohort of 378 unrelated children with partial epilepsy. Compound heterozygous variants of *ZFHX3* were identified in eight unrelated patients with partial epilepsy, including one with frequent nonconvulsive status epilepticus and two evolved from early spasms; the three patients with severe seizures also had neurodevelopmental abnormalities. However, all patients became seizure-free. A *Drosophila* model with *Zfh2* knockdown was established to investigate the association between *ZFHX3* and epilepsy. To explore the underlying mechanism of favorable outcomes, the genetic-dependent stages of *ZFHX3* orthologs were investigated, in which the expression of flies and mice was determined by RT-qPCR and that of humans was analyzed

using data from the Brainspan database. This study suggests that the *ZFHX3* gene is potentially a novel causative gene of partial epilepsy of childhood and infantile spasms with/without developmental abnormalities. The development-dependent expression pattern of *ZFHX3* explains the natural course of the illness.

Materials and methods

Patients

Patients were identified in a cohort of 378 unrelated children with partial epilepsy without acquired causes, which were recruited from five hospitals from 2019 to 2022, including the Second Affiliated Hospital of Guangzhou Medical University, Guangdong General Hospital, Shenzhen Children's Hospital, Shantou Chaonan Minsheng Hospital, and the Affiliated Brain Hospital of Nanjing Medical University. The clinical information of affected individuals was collected, including sex, seizure onset age, seizure types and frequency, response to antiepileptic drugs (AEDs), family history, and general and neurological examinations. Long-term video-electroencephalography (EEG) was performed to monitor epileptic discharges. Brain magnetic resonance imaging (MRI) scans were performed to detect structural abnormalities. Epileptic seizures and epilepsy syndromes were diagnosed according to the criteria of the Commission on Classification and Terminology of the ILAE (1989, 2001, 2010, 2017, and 2022).

This study was approved by the Ethics Committee of The Second Affiliated Hospital of Guangzhou Medical University (2020-h5-49), and written informed consent was obtained

from all patients or their parents.

Trios-based whole-exome sequencing and genetic analysis

Genomic DNA was extracted from blood samples of the probands and their parents (trios) and other available family members by using the Flexi Gene DNA kit (Qiagen, Hilden, Germany). Trios-based WES was performed with NextSeq500 sequencing instruments (Illumina, San Diego, CA, USA). Detailed sequencing methods were described in our previous studies.[8] A case-by-case analytical approach was adopted to identify candidate causative variants in each trio.[8] Primarily, the rare variants were prioritized with a minor allele frequency (MAF) < 0.005 in the gnomAD database (gnomad.broadinstitute.org). Then, potentially pathogenic variants were retained, including frameshift, nonsense, canonical splice site, initiation codon, in-frame variants, missense, and synonymous variants predicted to impact splicing. Last and importantly, possibly disease-causing variants in each individual were screened under five models: 1) epilepsy-associated gene; 2) de novo variant dominant; 3) autosomal recessive inheritance, including homozygous and compound heterozygous variants; 4) X-linked; and 5) cosegregation analysis if available. To identify novel potential epilepsy genes, genes with recurrently identified de novo, biallelic, hemizygous, and cosegregated variants were selected for further studies. *ZFHX3* appeared as a candidate gene with recurrent compound heterozygous variants in this cohort. All variants in *ZFHX3* in this study were validated by Sanger sequencing and annotated based on the transcript NM_006885.

Analysis of the burden of variants

Three specific statistical methods were used to analyze the association between *ZFHX3* and epilepsy, including recessive burden analysis,[24] aggregate frequency of variants,[25] and frequency of compound heterozygous variants.

For the burden of recessive variants, the *P* value was calculated as [1-cumulative binomial probability [(n-1, N, R)] according to a previous report,[24] where n is the observed biallelic variant number for *ZFHX3*, N is the number of trios (378 in this cohort), and R is the rate of *ZFHX3* variants by chance in populations. Considering that all patients were Han Chinese, the cutoff was set according to the MAF in the ExAC-East Asian population.

For aggregate frequency analysis, frequencies of identified variants between the case cohort and the controls were compared, including general and East Asian populations in the gnomAD database, general populations in the ExAC database, and the 33,444 persons without known neuropsychiatric conditions in the Epi25 WES Browser (https://epi25.broadinstitute.org/).[26]

For the control of compound heterozygous variants, we established a cohort of 1942 asymptomatic parents from trios, in whom the compound heterozygous variants were identified by detecting one of the paired variants in the child, based on the fact that one of the paired variants in a parent would transmit to the child. The number of identified compound heterozygous *ZFHX3* variants between the case cohort and the 1942 asymptomatic parent controls were compared.

Molecular structural analysis

Protein modeling was performed to predict the effects of missense variants on the molecular structure by using the I-TASSER tool (https://zhanggroup.org/I-TASSER/). Protein structures were visualized and analyzed by using the PyMOL Molecular Graphics System (Version 2.5; Schrödinger, LLC; New York, USA). Protein stability changes of missense variants were predicted by using the I-Mutant Suite (https://folding.biofold.org/cgi-bin/i-mutant2.0.cgi).

Drosophila experiments

Flies were reared at 25°C and 60-70% humidity with a standard cornmeal diet under a 12:12 h light and dark cycle. The *UAS-Zfh2-RNAi* line (CG1449, TH01656.N) was purchased from the TsingHua Fly Center. The *tub-Gal4* driver line and *Canton-s* line were donated by Prof. Liu Ji-Yong (Guangzhou Medical University, Guangzhou, China). *Zfh2* knockdown flies were generated by crossing the *UAS-Zfh2-RNAi* line with the *tub-Gal4* driver line. *Canton-s* was the wild-type line. The knockdown efficiency was detected by using reverse transcription quantitative PCR (RT-qPCR).

To evaluate the role of *Zfh2* deficiency in development, the body length of fly larvae was assessed, as in our previous study.[27] The larval stages of flies can be divided into three stages, i.e., the first (24 h), second (48 h), and third (72 h) instar larvae. The length of the larvae was measured using ImageJ NIH software (https://imagej.nih.gov/ij/).

To evaluate seizure-like behavior, the bang-sensitivity assay was conducted on flies 3-5 days

after eclosion.[28] Briefly, flies were anesthetized using CO_2 and transferred to clean vials for 0.5-1 h before testing. Three to seven flies were placed in each vial and stimulated mechanically using a vortex mixer (Lab Dancer, IKA, Germany) at maximum speed for 10 seconds.[28] The duration and percentage of seizure-like behavior were recorded.

To determine the impact of *Zfh2* knockdown on neuronal excitability, the electrophysiological activity of projection neurons was recorded. The fly brains were prepared for electrophysiological recording as described previously.[29] The standard external and internal solutions and patch pipette were prepared as described previously.[30] Spontaneous activities were acquired using the 700B amplifier, 1440B Digital-Analog converter, and pClamp 10.5 software (Molecular Devices, San Jose, CA, USA). A cell with an access resistance of <30 MΩ sample was used for analysis. Spontaneous EPSP (sEPSP) data > 1 mV were analyzed by Mini Analysis software.

Assessment of the *ZFHX3* ortholog expression profile

The mRNA expression levels of *ZFHX3* orthologs in different developmental stages in flies and mice were determined by RT-qPCR. For flies, the whole mRNA was extracted in five developmental stages, including third instar larvae, pupae, early adult (day 1), middle adult (day 5), and later adult (day 10). For mice, the mRNA of the frontal cortex was extracted in eight developmental stages, including the fetus, neonate (1 day), infant (1 week), toddle-period (2 weeks), preschool (4 weeks), juvenile-adult (10 weeks), middle-age (15 weeks), and old-age (32 weeks). The sequences of primers used in this study are listed in

Table S1. Total RNA was extracted by using the HiPure Universal RNA Mini Kit (Magen Biotechnology, Guangzhou, China). Reverse transcription was performed with the HiScript III RT SuperMix for qPCR (+gDNA wiper) (Vazyme, Nanjing, China) kit, and then qPCR was performed by the Taq Pro Universal SYBR qPCR Master Mix (Vazyme, Nanjing, China) with the LightCycler 480 System (Roche) tool.

Human RNA-seq data at different developmental stages (from 8 postconceptional weeks to 40 years) for multiple brain areas were obtained from the Brainspan database (http://www.brainspan.org/). RNA expression was normalized to reads per kilobase million (RPKM). The temporal expression curve was fitted by the third-order polynomial least squares to interpret the expression pattern of *ZFHX3* by GraphPad Prism 9.

Statistical analysis

R statistical software (v4.0.2) and GraphPad Prism 9 were used for statistical analysis. All quantitative data are presented as the mean ± standard error of the mean (SEM). The burden of recessive variants was analyzed according to a previous report.[24] The number and aggregated frequencies of *ZFHX3* variants of this cohort and controls were compared by a two-tailed Fisher's exact test. Student's t test was used to compare two independent samples, and the Mann-Whitney test was used to assess nonparametric data. The P value < 0.05 was considered to be statistically significant.

Data availability

Raw data were generated at the Institute of Neuroscience, The Second Affiliated Hospital of

Guangzhou Medical University. Derived data supporting the findings of this study are available from the corresponding author on request.

Results

Identification of *ZFHX3* variants

Compound heterozygous variants in *ZFHX3* were identified in eight unrelated cases with partial epilepsies, including c.314C>T/p.Pro105Leu & c.2282G>C/p.Gly761Ala, c.2419G>A/p.Glu807Lys & c.10853C>A/p.Pro3618Gln, c.2671T>C/p.Phe891Leu & c.9583_9584insT/p.Pro3195LeufsTer44, c.2686G>A/p.Ala896Thr & c.10439C>T/p.Ala3480Val, c.4125_4127del/p.Ala1376del & c.10853C>A/p.Pro3618Gln, c.5152A>C/p.Met1718Leu & c.10510G>C/p.Val3504Leu, c.6161C>T/p.Ala2054Val & c.10445G>T/p.Ser3482Ile, and c.10445G>T/p.Ser3482Ile & c.10853C>A/p.Pro3618Gln (**Table 1 and Figure 1**). The eight pairs of compound heterozygous variants consisted of eleven missense variants, one frameshift truncation, and one in-frame deletion. The missense variant p.Ser3482Ile was recurrently identified in two cases (Cases 7 & 8), and the variant p.Pro3618Gln was recurrently identified in three cases (Cases 2, 5, & 8). All of the *ZFHX3* compound heterozygous variants were inherited from their asymptomatic parents, consistent with the Mendelian autosomal recessive inheritance pattern.

The identified variants presented no or low frequencies in the gnomAD database (MAF < 0.005) (**Table 2**). Six variants were not present in the normal control of the Epi25 WES Browser, while the other seven variants presented extremely low frequencies (MAF <

0.0005). None of the variants presented homozygous states in gnomAD.

When the burden of recessive variants was analyzed,[24] the number of recessive *ZFHX3* variants identified in this cohort was significantly greater than the expected number by chance in the East Asian population (MAF < 0.005, $P = 1.60\times10^{-4}$). The aggregate frequency of variants identified in the case cohort was significantly higher than that in the controls, including the controls of the gnomAD-all population ($P = 2.30\times10^{-13}$), the controls of the gnomAD-East Asian population ($P = 4.36\times10^{-2}$), the general population of the ExAC database ($P = 2.34\times10^{-13}$), and the normal controls of the Epi25 WES Browser ($P = 3.56\times10^{-18}$) (**Table 2**). The frequency of compound heterozygous *ZFHX3* variants in the case cohort was significantly higher than that in the control cohort of 1942 asymptomatic parents. (8/378 vs 5/1942, $P = 2.80\times10^{-4}$).

None of the eight patients had pathogenic or likely pathogenic variants in the genes known to be associated with epileptic phenotypes.[31]

Clinical features of the cases with *ZFHX3* variants

The detailed clinical characteristics of the eight unrelated cases with *ZFHX3* variants are summarized in **Table 1**. The onset age of seizures ranged from 5 months to 13 years old, with a median onset age of 5 years. The patients were all diagnosed with partial epilepsy, including three cases with neurodevelopmental abnormalities, of whom two presented frequent spasms (Cases 4 & 6) at the early stage of the illness and one experienced nonconvulsive status epilepticus (Case 7). The other five cases exhibited only infrequent (yearly) focal seizures or

focal-origin generalized tonic-clonic seizures (Cases 1-3, 5, 8). Focal, multifocal, and/or diffuse epileptic discharges were recorded in their EEG (**Figure 1E**). The brain MRI was normal in all cases. A seizure-free status was achieved in all eight patients.

Molecular effect and functional prediction of *ZFHX3* variants

The *ZFHX3* protein contains 23 zinc finger motifs and 4 homeodomains. Two variants, p.Glu807Lys and p.Ala1376del, were located in the zinc finger motifs, and other variants were scattered between zinc fingers and/or homeodomains (**Figure 2A**). The variants p.Pro3618Gln, located in the last part of the C-terminus, were repetitively identified in three of five mild cases (Cases 2, 5, & 8). Similarly, the frameshift variant (p.Pro3195LeufsTer44), which truncated the C-terminus, was also identified in a mild case (Case 3). The remaining mild case (Case 1) had two variants located in the N-terminus.

The damaging effect of missense variants was analyzed by protein modeling. Two missense variants, p.Glu807Lys and p.Ala896Thr, were predicted to alter hydrogen bonding with surrounding residues. Six variants were predicted to decrease the protein stability with a □□G value less than -0.5 kcal/mol (**Figure 2B**). All the variants were predicted to be damaging by at least one *in silico* tool (**Table S2**).

Knockdown of *Zfh2* in *Drosophila* led to increased susceptibility to seizures

To validate the association between *ZFHX3* and epilepsy, a *Drosophila* model of *Zfh2* knockdown was established, with a knockdown efficiency of approximately 66% (**Figure 3A**). The larval development of *Zfh2* knockdown flies was initially investigated. The larval

body length of *Zfh2* knockdown flies was similar to that of the *UAS-Zfh2-RNAi* control flies (**Figure 3B**).

A Bang-sensitivity assay was performed in *Zfh2* knockdown flies and *UAS-Zfh2-RNAi* control flies to assess susceptibility to seizures. The three phases of seizure activity in the Bang-sensitivity test were observed, including seizure, paralysis, and recovery (**Figure 3C**). The percentage of seizure-like behaviors in the *Zfh2* knockdown flies was significantly higher than that in the *UAS-Zfh2-RNAi* control [18.66 ± 2.09% (n = 15) vs 4.06 ± 0.87% (n = 9); $P < 0.0001$], the *Canton-s* control [18.66 ± 2.09% (n = 15) vs 6.88 ± 0.89% (n = 7); $P = 0.0013$], and the *tub-Gal4* control [18.66 ± 2.09% (n = 15) vs 3.56 ± 1.03% (n = 7); $P < 0.0001$] (**Figure 3D**). The duration of seizure-like behavior in *Zfh2* knockdown flies was also longer than that of the controls (**Figure 3E**).

The effect of *Zfh2* deficiency on the electrophysiological activity of projection neurons, which are important excitatory neurons in the central nervous system of *Drosophila*,[32] was examined (**Figure 4A, B**). The frequency of sEPSPs in *Zfh2* knockdown flies was significantly higher than that in wild-type flies [0.6312 ± 0.06 Hz (n = 7) vs 0.09907 ± 0.01 Hz (n = 7); $P < 0.0001$] (**Figure 4C)**. There was no significant difference in the amplitude of sEPSPs between the *Zfh2* knockdown flies and WT flies [1.405 ± 0.2039 pA (n = 7) vs 1.228 ± 0.1486 pA (n = 7), $P = 0.0888$] (**Figure 4D**).

The temporal expression stage of *ZFHX3* orthologs

Infantile spasms are generally a severe form of epilepsy with a poor prognosis in the

majority of cases.[33] In this study, the two patients with early spasms presented favorable outcomes. Recent studies have indicated that the gene-dependent (expression) stage (GDS) is associated with the natural course and outcomes of illness.[14, 34-36] We thus analyzed the temporal expression pattern of *ZFHX3* orthologs. In *Drosophila*, the expression of *Zfh2* was high in larvae, decreased in pupae and early adults, and increased in later adults (**Figure 5A**). In mice, the expression level of *Zfhx3* was high in the fetus, decreased dramatically after birth, and slightly increased in later adults (32 weeks) (**Figure 5B**). We further analyzed the temporal expression pattern of *ZFHX3* in the human brain by using data from BrainSpan. *ZFHX3* was also highly expressed in the embryonic stage, decreased dramatically in childhood with a nadir at approximately 10 years old, and slightly increased at approximately 30 years old (**Figure 5C**).

Discussion

The zinc finger homeobox 3 gene (*ZFHX3*, OMIM *104155), also known as AT motif-binding transcription factor 1 gene (*ATBF1*), encodes a transcription factor with 4 homeodomains and 23 zinc finger motifs. In this study, we identified compound heterozygous *ZFHX3* variants in eight unrelated patients with partial epilepsy, including two with early spasms. The *ZFHX3* gene presented significantly higher excesses of variants in the case cohort, including a higher excess of biallelic variants than the expected number of East Asian populations, higher aggregated frequencies than that in gnomAD, and a higher frequency of compound heterozygous variants than that in the asymptomatic parent controls. Knockdown of *Zfh2* in flies caused increased susceptibility to seizures and abnormal firing of

neurons. All patients achieved seizure-free, although two patients evolved from early spasms. The analysis of the temporal expression profile indicated that *ZFHX3* orthologs were highly expressed in the embryonic stage and decreased dramatically in childhood, which is correlated with the favorable outcomes of the patients. This study suggested that *ZFHX3* is potentially a novel causative gene of childhood partial epilepsy and infantile spasms with/without neurodevelopmental abnormalities.

The *ZFHX3* gene is highly conserved with homologs in flies, zebrafish, mice, and humans. It is ubiquitously expressed, especially in the developing brain. *ZFHX3* plays vital roles in multiple biological processes, including embryonic development, cell proliferation, neuronal differentiation, and neuronal death.[37-39] In mice, homozygous knockout of *Zfhx3* led to prenatal lethality with complete penetrance, while heterozygous knockout resulted in growth restriction and postnatal lethality with incomplete penetrance.[40] In zebrafish, knockdown of *Zfxh3* caused significantly increased pentylenetetrazol-induced seizures.[41] In flies, previous studies showed that the majority of knockout/knockdown *Zfh2* lines exhibited preadult lethality (http://flybase.org/reports/FBgn0004607#phenotypes). This study identified biallelic *ZFHX3* variants in eight unrelated patients with partial epilepsy with/without neurodevelopmental abnormalities, and the knockdown of *Zfh2* in *Drosophila* led to increased susceptibility to seizures and abnormal firing of neurons. The recurrent epileptic and/or neurodevelopmental phenotypes across species supported the association between *ZFHX3* and epilepsy and neurodevelopmental abnormalities.

Data from variants in the human genome reveal that *ZFHX3* is intolerant to LOF variants,

including constraint indexes such as the probability of being LOF intolerant (pLI),[42] the LOF observed/expected upper bound fraction (LOEUF),[42] and the probability of haploinsufficiency (pHaplo).[43] The *ZFHX3* gene has a pLI of 0.997 (> 0.9), LOEUF of 0.147 (< 0.35), and pHaplo of 1 (≥ 0.86), all indicating that *ZFHX3* is intolerant to heterozygous LOF variants. Considering the recurrent lethal and neurodevelopmental/epileptic phenotypes in *Zfhx3* knockout/knockdown animals, it is possible that severe *ZFHX3* deficiency, such as biallelic null variants, will cause early lethality, while moderate *ZFHX3* deficiency, such as heterozygous null variants or biallelic missense variants with moderate damaging effects, is potentially associated with epilepsy and/or neurodevelopmental abnormalities. In this study, most of the variants were located outside the functional domains and predicted to be without hydrogen bond changes with surrounding residues, indicating mild damaging effects, which potentially explain the pathogenesis of compound heterozygous variants. Three of the patients with a mild phenotype had an identical variant p.Pro3618Gln, which was located in the last part of the C-terminus and presented a low MAF (0.000301) (instead of not present) in the general population, indicating a potentially mild damaging effect. One patient with a mild phenotype had a frameshift variant with truncation at the C-terminus, which was inherited from the asymptomatic father and presented with low MAF (instead of not present), thus potentially being of mild damage. These findings suggested a potential genotype-phenotype correlation.

The ZFHX3 protein, a transcription factor containing 23 C_2H_2-type zinc fingers and 4 homeodomains, belongs to the C_2H_2-type zinc finger protein family, which plays an essential

role in neurodevelopment.[44] Previously, *ZFHX3* de novo variants were occasionally detected in patients with neurodevelopmental disorders, including four variants in autism spectrum disorder,[45-47] three variants in developmental disorder,[48] and one variant in development and epileptic encephalopathy (**Table S3**),[49] suggesting a potential role in neurodevelopmental disorders. In the present study, neurodevelopment abnormalities were observed in three patients. These data indicated a possible association between *ZFHX3* and neurodevelopmental disorders. Further studies are needed to determine the whole phenotypic spectrum of *ZFHX3*.

Infantile spasms are generally a severe form of epilepsy with poor outcomes.[4] Clinically, approximately 33% of patients with spasms present favorable outcomes,[33] but the underlying mechanism is unknown. Our recent study showed that GDS is associated with the natural course and outcomes of diseases.[14, 34-36] In this study, the two patients with early spasms presented favorable outcomes. Studies on the temporal expression stage showed that *ZFHX3* orthologs were highly expressed in the embryonic stage and decreased dramatically in childhood, which is potentially one of the explanations for the favorable outcomes. Considering that the expression of *ZFHX3* was slightly increased at approximately 30 years old, long-term follow-up is required to observe the future evolution of the disease.

In conclusion, this study suggested that *ZFHX3* is potentially a novel causative gene of partial epilepsy and infantile spasms with/without neurodevelopmental abnormalities. The correlation between the outcome and gene expression stage provided insight into the underlying mechanism of the natural course of illness, potentially being helpful in the management of the patients.

Funding

This study was supported by grants from the National Natural Science Foundation of China (No. 82271505, No. 81870903, and No. 81971216); Science and Technology Project of Guangzhou (Grant Nos 202201020106), Multicenter Clinical Research Fund Project of the Second Affiliated Hospital of Guangzhou Medical University (Grant Nos 010G271099, 2020-LCYJ-DZX-03, and 2021-LCYJ-DZX-02), and Scientific Research Project of Guangzhou Education Bureau (Grant No. 202235395). The funders had no role in the study design, data collection and analysis, and the decision to publish or in manuscript preparation.

Disclosure

The authors declare no conflicts of interest.

Acknowledgments

We thank the patients and their families for participating in this study. We thank Prof. Liu Ji-Yong for donating the *tub-Gal4* driver line and *Canton-s* line flies and Schrödinger (New York, NY, USA) for supporting open-source PyMOL software.

Author Information

Conceptualization: W.P.L., Y.H.Y., N.H., J.D.Q.; Data Curation: M.F.H., L.H.L., S.L., J.W., Q.X.Z., S.L.H., D.F.Z., X.R.L., B.M.L., H.Y.M., P.Z.; Formal analysis: M.F.H., S.L.; Investigation: M.F.H., J.J.G., S.L.; Resources: W.P.L., Y.H.Y., X.R.L., N.H.; Software: M.F.H., P.Y.W.; Visualization: M.F.H., P.Y.W.; Writing-original draft: M.F.H., L.H.L., S.L.;

Writing-review and editing: M.F.H., L.H.L., S.L., N.H., Y.H.Y., W.P.L.

Supporting information

Supplementary table 1. Sequences of primers used in this study.

Supplementary table 2. Genetic features of *ZFHX3* variants identified in this study.

Supplementary table 3. Previously reported *ZFHX3* variants and associated phenotypes.

Supplementary reference (only for review). *PCDH15* in self-limited partial epilepsy and the mechanism of distinct phenotypes (Revised in Annuals of Neurology).

References

1. Aaberg KM, Gunnes N, Bakken IJ, et al. Incidence and Prevalence of Childhood Epilepsy: A Nationwide Cohort Study. *Pediatrics*. May 2017;139(5)doi:10.1542/peds.2016-3908
2. Wirrell EC, Grossardt BR, Wong-Kisiel LC, Nickels KC. Incidence and classification of new-onset epilepsy and epilepsy syndromes in children in Olmsted County, Minnesota from 1980 to 2004: a population-based study. *Epilepsy Res*. Jun 2011;95(1-2):110-8. doi:10.1016/j.eplepsyres.2011.03.009
3. Eltze CM, Chong WK, Cox T, et al. A population-based study of newly diagnosed epilepsy in infants. *Epilepsia*. Mar 2013;54(3):437-45. doi:10.1111/epi.12046
4. Zuberi SM, Wirrell E, Yozawitz E, et al. ILAE classification and definition of epilepsy syndromes with onset in neonates and infants: Position statement by the ILAE Task Force on Nosology and Definitions. *Epilepsia*. Jun 2022;63(6):1349-1397. doi:10.1111/epi.17239
5. Dunn P, Albury CL, Maksemous N, et al. Next Generation Sequencing Methods for Diagnosis of Epilepsy Syndromes. *Front Genet*. 2018;9:20. doi:10.3389/fgene.2018.00020
6. Liu L, Chen ZR, Xu HQ, et al. DEPDC5 Variants Associated Malformations of Cortical Development and Focal Epilepsy With Febrile Seizure Plus/Febrile Seizures: The Role of Molecular Sub-Regional Effect. *Front Neurosci*. 2020;14:821. doi:10.3389/fnins.2020.00821
7. Lemke JR, Lal D, Reinthaler EM, et al. Mutations in GRIN2A cause idiopathic focal epilepsy with rolandic spikes. *Nat Genet*. Sep 2013;45(9):1067-72. doi:10.1038/ng.2728
8. Wang J, Qiao JD, Liu XR, et al. UNC13B variants associated with partial epilepsy with favourable outcome. *Brain*. Nov 29 2021;144(10):3050-3060. doi:10.1093/brain/awab164
9. He N, Guan BZ, Wang J, et al. HCFC1 variants in the proteolysis domain are associated with X-linked idiopathic partial epilepsy: Exploring the underlying mechanism. *Clin Transl*

Med. Jun 2023;13(6):e1289. doi:10.1002/ctm2.1289
10. Luo S, Liu ZG, Wang J, et al. Recessive LAMA5 Variants Associated With Partial Epilepsy and Spasms in Infancy. *Front Mol Neurosci*. 2022;15:825390. doi:10.3389/fnmol.2022.825390
11. Li X, Bian WJ, Liu XR, et al. BCOR variants are associated with X-linked recessive partial epilepsy. *Epilepsy Res*. Nov 2022;187:107036. doi:10.1016/j.eplepsyres.2022.107036
12. Chen Z, Luo S, Liu ZG, et al. CELSR1 variants are associated with partial epilepsy of childhood. *Am J Med Genet B Neuropsychiatr Genet*. Oct 2022;189(7-8):247-256. doi:10.1002/ajmg.b.32916
13. Tian MQ, Liu XR, Lin SM, et al. Variants in BRWD3 associated with X-linked partial epilepsy without intellectual disability. *CNS Neurosci Ther*. Feb 2023;29(2):727-735. doi:10.1111/cns.14057
14. Zou DF, Li XY, Lu XG, et al. Association of FAT1 with focal epilepsy and correlation between seizure relapse and gene expression stage. *Seizure*. Mar 11 2023;doi:10.1016/j.seizure.2023.03.003
15. Strug LJ, Clarke T, Chiang T, et al. Centrotemporal sharp wave EEG trait in rolandic epilepsy maps to Elongator Protein Complex 4 (ELP4). *Eur J Hum Genet*. Sep 2009;17(9):1171-81. doi:10.1038/ejhg.2008.267
16. Kato M, Yamagata T, Kubota M, et al. Clinical spectrum of early onset epileptic encephalopathies caused by KCNQ2 mutation. *Epilepsia*. Jul 2013;54(7):1282-7. doi:10.1111/epi.12200
17. Ohba C, Kato M, Takahashi N, et al. De novo KCNT1 mutations in early-onset epileptic encephalopathy. *Epilepsia*. Sep 2015;56(9):e121-8. doi:10.1111/epi.13072
18. Lemke JR, Hendrickx R, Geider K, et al. GRIN2B mutations in West syndrome and intellectual disability with focal epilepsy. *Ann Neurol*. Jan 2014;75(1):147-54. doi:10.1002/ana.24073
19. Saitsu H, Kato M, Mizuguchi T, et al. De novo mutations in the gene encoding STXBP1 (MUNC18-1) cause early infantile epileptic encephalopathy. *Nat Genet*. Jun 2008;40(6):782-8. doi:10.1038/ng.150
20. Campeau PM, Kasperaviciute D, Lu JT, et al. The genetic basis of DOORS syndrome: an exome-sequencing study. *Lancet Neurol*. Jan 2014;13(1):44-58. doi:10.1016/S1474-4422(13)70265-5
21. Sadleir LG, Mountier EI, Gill D, et al. Not all SCN1A epileptic encephalopathies are Dravet syndrome: Early profound Thr226Met phenotype. *Neurology*. Sep 5 2017;89(10):1035-1042. doi:10.1212/WNL.0000000000004331
22. Archer HL, Evans J, Edwards S, et al. CDKL5 mutations cause infantile spasms, early onset seizures, and severe mental retardation in female patients. *J Med Genet*. Sep 2006;43(9):729-34. doi:10.1136/jmg.2006.041467
23. Moey C, Topper S, Karn M, et al. Reinitiation of mRNA translation in a patient with X-linked infantile spasms with a protein-truncating variant in ARX. *Eur J Hum Genet*. May 2016;24(5):681-9. doi:10.1038/ejhg.2015.176
24. Martin HC, Jones WD, McIntyre R, et al. Quantifying the contribution of recessive

coding variation to developmental disorders. *Science*. Dec 7 2018;362(6419):1161-1164. doi:10.1126/science.aar6731
25. Strande NT, Riggs ER, Buchanan AH, et al. Evaluating the Clinical Validity of Gene-Disease Associations: An Evidence-Based Framework Developed by the Clinical Genome Resource. *Am J Hum Genet*. Jun 1 2017;100(6):895-906. doi:10.1016/j.ajhg.2017.04.015
26. Epi25 Collaborative. Electronic address sbuea, Epi C. Ultra-Rare Genetic Variation in the Epilepsies: A Whole-Exome Sequencing Study of 17,606 Individuals. *Am J Hum Genet*. Aug 1 2019;105(2):267-282. doi:10.1016/j.ajhg.2019.05.020
27. Liu CQ, Qu XC, He MF, et al. Efficient strategies based on behavioral and electrophysiological methods for epilepsy-related gene screening in the Drosophila model. *Front Mol Neurosci*. 2023;16:1121877. doi:10.3389/fnmol.2023.1121877
28. Parker L, Howlett IC, Rusan ZM, Tanouye MA. Seizure and epilepsy: studies of seizure disorders in Drosophila. *Int Rev Neurobiol*. 2011;99:1-21. doi:10.1016/B978-0-12-387003-2.00001-X
29. Gu H, O'Dowd DK. Cholinergic synaptic transmission in adult Drosophila Kenyon cells in situ. *J Neurosci*. Jan 4 2006;26(1):265-72. doi:10.1523/JNEUROSCI.4109-05.2006
30. Qiao J, Yang S, Geng H, Yung WH, Ke Y. Input-timing-dependent plasticity at incoming synapses of the mushroom body facilitates olfactory learning in Drosophila. *Curr Biol*. Nov 21 2022;32(22):4869-4880 e4. doi:10.1016/j.cub.2022.09.054
31. Wang J, Lin ZJ, Liu L, et al. Epilepsy-associated genes. *Seizure*. Jan 2017;44:11-20. doi:10.1016/j.seizure.2016.11.030
32. Ran D, Cai S, Wu H, Gu H. Di (2-ethylhexyl) phthalate modulates cholinergic mini-presynaptic transmission of projection neurons in Drosophila antennal lobe. *Food Chem Toxicol*. Sep 2012;50(9):3291-7. doi:10.1016/j.fct.2012.03.070
33. Chourasia N, Yuskaitis CJ, Libenson MH, et al. Infantile spasms: Assessing the diagnostic yield of an institutional guideline and the impact of etiology on long-term treatment response. *Epilepsia*. May 2022;63(5):1164-1176. doi:10.1111/epi.17209
34. He N, Li B, Lin ZJ, Zhou P, Su T, Liao WP. Common genetic epilepsies, pathogenicity of genes/variants, and genetic dependence. *Seizure*. Jul 2023;109:38-39. doi:10.1016/j.seizure.2023.05.008
35. Lin SM, Su T, Qiao JD, et al. PCDH15 in self-limited partial epilepsy and the mechanism of distinct phenotypes (Revised in Annuals of Neurology, attached to supplementary reference). 2023;
36. Li B, Bian W-J, Zhou P, et al. Genetic Dependence and Genetic Diseases. *bioRxiv*. 2023-08-05 2023;doi:10.1101/2023.08.02.551736
37. Jung CG, Kim HJ, Kawaguchi M, et al. Homeotic factor ATBF1 induces the cell cycle arrest associated with neuronal differentiation. *Development*. Dec 2005;132(23):5137-45. doi:10.1242/dev.02098
38. Ishii Y, Kawaguchi M, Takagawa K, et al. ATBF1-A protein, but not ATBF1-B, is preferentially expressed in developing rat brain. *J Comp Neurol*. Oct 6 2003;465(1):57-71. doi:10.1002/cne.10807

39. Jung CG, Uhm KO, Miura Y, et al. Beta-amyloid increases the expression level of ATBF1 responsible for death in cultured cortical neurons. *Molecular neurodegeneration*. Jul 5 2011;6:47. doi:10.1186/1750-1326-6-47
40. Sun X, Fu X, Li J, et al. Heterozygous deletion of Atbf1 by the Cre-loxP system in mice causes preweaning mortality. *Genesis*. Nov 2012;50(11):819-27. doi:10.1002/dvg.22041
41. Fuller TD, Westfall TA, Das T, Dawson DV, Slusarski DC. High-throughput behavioral assay to investigate seizure sensitivity in zebrafish implicates ZFHX3 in epilepsy. *J Neurogenet*. Mar-Jun 2018;32(2):92-105. doi:10.1080/01677063.2018.1445247
42. Karczewski KJ, Francioli LC, Tiao G, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. *Nature*. May 2020;581(7809):434-443. doi:10.1038/s41586-020-2308-7
43. Collins RL, Glessner JT, Porcu E, et al. A cross-disorder dosage sensitivity map of the human genome. *Cell*. Aug 4 2022;185(16):3041-3055 e25. doi:10.1016/j.cell.2022.06.036
44. Al-Naama N, Mackeh R, Kino T. C(2)H(2)-Type Zinc Finger Proteins in Brain Development, Neurodevelopmental, and Other Neuropsychiatric Disorders: Systematic Literature-Based Analysis. *Front Neurol*. 2020;11:32. doi:10.3389/fneur.2020.00032
45. Wang T, Guo H, Xiong B, et al. De novo genic mutations among a Chinese autism spectrum disorder cohort. *Nat Commun*. Nov 8 2016;7:13316. doi:10.1038/ncomms13316
46. Hashimoto R, Nakazawa T, Tsurusaki Y, et al. Whole-exome sequencing and neurite outgrowth analysis in autism spectrum disorder. *J Hum Genet*. Mar 2016;61(3):199-206. doi:10.1038/jhg.2015.141
47. Kosmicki JA, Samocha KE, Howrigan DP, et al. Refining the role of de novo protein-truncating variants in neurodevelopmental disorders by using population reference samples. *Nat Genet*. Apr 2017;49(4):504-510. doi:10.1038/ng.3789
48. Deciphering Developmental Disorders S. Prevalence and architecture of de novo mutations in developmental disorders. *Nature*. Feb 23 2017;542(7642):433-438. doi:10.1038/nature21062
49. Epi KC, Epilepsy Phenome/Genome P, Allen AS, et al. De novo mutations in epileptic encephalopathies. *Nature*. Sep 12 2013;501(7466):217-21. doi:10.1038/nature12439

Figure legends

Figure 1 Genetic data and representative EEG recordings of the cases with *ZFHX3* variants. (A) Pedigrees of eight cases with compound heterozygous *ZFHX3* variants and their corresponding phenotypes. PE, partial epilepsy; FS, febrile seizures; NCSE, nonconvulsive status epilepticus; NDD, neurodevelopmental delay. (B) DNA sequencing chromatogram of *ZFHX3* variants. Arrows indicate the position of the variants. (C) EEG of case 2 showed right frontal-centro-temporal sharp-slow waves. (D) EEG of case 5 showed right temporal spike-slow waves. (E) EEG of case 6 showed right frontal spike-slow waves (left) and generalized poly-spike-slow waves (right). (F) EEG of case 8 showed bilateral occipital-temporal sharp-slow waves.

Figure 2 Schematic illustration of *ZFHX3* variants. (A) Schematic illustration of zinc finger homeobox protein 3 and locations of *ZFHX3* variants identified in this study. Two variants of the same height were a pair of biallelic variants. The red color represents cases with severe partial epilepsy with neurodevelopmental abnormalities. The blue color represents cases with mild partial epilepsy. (B) Hydrogen bond changes (red) and free energy stability changes ($\Delta\Delta$G, Kcal/mol) of the variants from the present study.

Figure 3 Functional studies on *Zfh2* knockdown flies (A) Relative *Zfh2* mRNA expression levels of the knockdown flies and the *UAS-Zfh2-RNAi* controls. (B) The body length of *Zfh2* knockdown and *UAS-Zfh2-RNAi* control larvae. (C) Behavior in the Bang-sensitive test; the

three phases observed in *Zfh2* knockdown flies were seizure, paralysis, and recovery. (D) Seizure-like behaviors occurred at a higher rate in *Zfh2* knockdown flies (*tub-Gal4 > UAS-Zfh2-RNAi*) than in the *UAS-Zfh2-RNAi* line. (E) The recovery time from seizure-like behaviors of *Zfh2* knockdown flies was longer than that of the controls.

Figure 4 *Zfh2* knockdown induces increased neural excitability in projection neurons. (A) Whole-cell recording in the fly brain. (B) Representative traces of projection neuron sEPSPs in *Canton-s* wild-type (WT) flies and *Zfh2* knockdown flies. (C) The frequency of sEPSPs was significantly higher in *Zfh2* knockdown flies than in wild-type flies. (D) There was no difference in the amplitude of sEPSPs between *Zfh2* knockdown flies and wild-type flies.

Figure 5 The temporal expression profile of *ZFHX3* orthologs. (A) Schematic illustration of the developmental stages of *Drosophila melanogaster* (left) and the temporal expression of *Zfh2* in flies (right). The mRNA levels of *Zfh2* were examined by RT-qPCR. The *Zfh2* mRNA levels were normalized to the mRNA levels of the third instar larvae. (B) Schematic illustration of the developmental stages of mice (left) and the temporal expression of *Zfhx3* in the frontal cortex of mice (right). The *Zfhx3* mRNA levels were normalized to the mRNA levels of fetal mice. (C) Temporal expression pattern of *ZFHX3* in the human brain. RPKM, reads per kilobase per million mapped reads.

Table 1. Clinical features of the individuals with *ZFHX3* variants

Case	Variants (NM_006885)	Sex	Age	Onset age	Sz course	Sz-free duration	Effective AEDs	EEG	Brain MRI	Development	Diagnosis
Case 1	c.314C>T/p.Pro105Leu c.2282G>C/p.Gly761Ala	M	juvenile	childhood	sGTCS, 1-2 times/yr	1 yr	-	Bilateral spike-slow waves with frontal dominance	Normal	Normal	PE
Case 2	c.2419G>A/p.Glu807Lys c.10853C>A/p.Pro3618Gln	F	childhood	childhood	sGTCS, 1-5 times/mo	1.5 yrs	LTG	Right frontal-centro-temporal sharp-slow waves	Normal	Normal	PE
Case 3	c.2671T>C/p.Phe891Leu c.9583_9584insT/ p.Pro3195LeufsTer44	M	childhood	toddler	CPS, 2-3 times/yr	1 yr	OXC	Spike-slow waves in bilateral frontal-central area with right dominance	Normal	Normal	PE
Case 4	c.2686G>A/p.Ala896Thr c.10439C>T/p.Ala3480Val	M	toddler	infant	Spasms, CPS >10 times/day	2 yrs	LEV, LTG	Poly-spike-slow waves	Normal	GDD	Spasms, PE
Case 5	c.4125_4127del/p.Ala1376del c.10853C>A/p.Pro3618Gln	M	childhood	childhood	sGTCS, 3 times for 2 yrs; CPS, twice at for 1 yr	5 yrs	OXC, VPA	Right temporal spike-slow waves	Normal	Normal	PE
Case 6	c.5152A>C/p.Met1718Leu c.10510G>C/p.Val3504Leu	M	childhood	toddler	Spasms 5-7 times/day for 4 mos; then CPS 0-10 times/day	9 yrs	VPA, LEV, LTG	Right frontal spike-slow waves with tendency of generalization	Normal	GDD	Spasms, PE
Case 7	c.6161C>T/p.Ala2054Val c.10445G>T/p.Ser3482Ile	M	childhood	infant	FS, 3 times; sGTCS and CPS twice/week; NCSE 2-3 times for 1 yr	6 mos	VPA, PER, LEV	Left frontal, temporal, and occipital 1.5-2 Hz spike-slow waves; Diffused 1.5-2.5 Hz spike-slow waves	Normal	GDD	PE
Case 8	c.10445G>T/p.Ser3482Ile c.10853C>A/p.Pro3618Gln	F	childhood	childhood	sGTCS, 2 times for 2 yr	1.5 yrs	TPM	Bilateral occipital-temporal sharp-slow waves	Normal	Normal	PE

Abbreviations: AEDs, antiepileptic drugs; CPS, complex partial seizures; GDD, global developmental delay; EEG, electroencephalogram; FS, febrile seizures; LEV, levetiracetam; LTG, lamotrigine; NCSE, nonconvulsive status epilepticus; OXC, oxcarbazepine; PE, partial epilepsy; PER, perampanel; Sz, seizures; sGTCS, secondary generalized tonic-clonic seizures; TPM, topamax; VPA, valproate; mo, month; yr, year

Table 2. Analysis of the aggregate frequency of *ZFHX3* variants identified in this study

Identified *ZFHX3* variants	Allele count/number in this study	Allele count/number in controls of gnomAD-all populations	Allele count/number in controls of gnomAD-East Asian populations	Allele count/number in ExAC populations	Allele count/number in controls of Epi25 WES browser	Number of Homozygotes in controls of gnomAD
c.314C>T/p.Pro105Leu	1/756	34/112352	25/9804	23/104844	15/66264	0
c.2282G>C/p.Gly761Ala	1/756	22/109332	11/9042	16/119178	10/66888	0
c.2419G>A/p.Glu807Lys	1/756	10/109406	0/9046	6/121404	1/66888	0
c.2671T>C/p.Phe891Leu	1/756	−/−	−/−	−/−	−/−	-
c.2686G>A/p.Ala896Thr	1/756	24/108908	1/9046	17/119382	2/66868	0
c.4125_4127del/p.Ala1376del	1/756	8/120262	8/9962	6/121388	0/66888	0
c.5152A>C/p.Met1718Leu	1/756	2/109258	2/9022	1/119740	1/66886	0
c.6161C>T/p.Ala2054Val	1/756	2/105822	1/8870	2/115778	−/−	0
c.9583_9584insT/p.Pro3195LeufsTer44	1/756	8/119370	2/9686	60/118664	−/−	0
c.10439C>T/p.Ala3480Val	1/756	7/119956	7/9942	5/118166	0/66884	0
c.10445G>T/p.Ser3482Ile	2/756	30/119978	30/9938	25/117840	9/66884	0
c.10510G>C/p.Val3504Leu	1/756	−/−	−/−	−/−	−/−	-
c.10853C>A/p.Pro3618Gln	3/756	35/116270	35/9678	23/112466	5/66408	0
Total	16/756	182/120262	122/9962	184/121404	43/66888	0
P value[†]		2.3×10^{-13}	4.36×10^{-2}	2.34×10^{-13}	3.56×10^{-18}	
OR (95% CI)		14.27 (7.94-23.95)	1.74 (0.96-2.97)	14.25 (7.93-23.91)	33.61 (18.85-59.94)	

[†]P values and odds ratios were estimated with a 2-sided Fisher's exact test.

Abbreviations: CI, confidence interval; gnomAD, Genome Aggregation Database; ExAC, Exome Aggregation Consortium; Epi25, a whole-exome sequencing case-control study of epilepsy; OR, odds ratio


A
PE
Spasms
FS
NCSE
NDD
Case 1
m1:p.Pro105Leu
m2:p.Gly761Ala
m1/+
m2/+
m1/m2
Case 2
m3:p.Glu807Lys
m4:p.Pro3618Gln
m3/+
m4/+
+/+
m3/m4
Case 3
m5:p.Pro3195Leufs*44
m6:p.Phe891Leu
m5/+
m6/+
m5/m6
Case 4
m7:p.Ala896Thr
m8:p.Ala3480Val
m7/+
m8/+
m7/m8
Case 5
m4:p.Pro3618Gln
m9:p.Ala1376del
m4/+
m9/+
m4/m9
m4/+
Case 6
m10:p.Met1718Leu
m11:p.Val3504Leu
m10/+
m11/+
m10/m11
Case 7
m12:p.Ala2054Val
m13:p.Ser3482Ile
m12/+
m13/+
m12/m13
Case 8
m4:p.Pro3618Gln
m13:p.Ser3482Ile
m4/+
m13/+
m4/m13
B
Proband
Father
Mother
c.3314C>T
c.2282G>C
c.2419G>A
c.10853C>A
c.9583_9584insT
c.2671T>C
c.2686G>A
c.10439C>T
c.10853C>A
c.4125_4127delTGC
c.5152A>C
c.10510G>C
c.6161C>T
c.10445G>T
c.10853C>A
c.10445G>T
C
D
E
F
Fp1-AV
Fp2-AV
F3-AV
F4-AV
C3-AV
C4-AV
P3-AV
P4-AV
O1-AV
O2-AV
T1-AV
T2-AV
F7-AV
F8-AV
T3-AV
T4-AV
T5-AV
T6-AV
Fz-AV
Cz-AV
Pz-AV
200μV
70μV
1Sec


A
p.Ala896Thr
p.Ala3480Val
p.Ser3482Ile
p.Pro3618Gln
p.Phe891Leu
p.Ala2054Val
p.Pro3195Leufs*44
p.Glu807Lys
p.Gly761Ala
p.Pro105Leu
p.Met1718Leu
p.Val3504Leu
p.Ala1376del
1
3703
Homeobox
Zinc finger
Motif
Compound heterozygous
B
Pro105Leu
DDG = -0.79 Kcal/mol
Gly761Ala
DDG = -0.49 Kcal/mol
Glu807Lys
DDG = -0.60 Kcal/mol
Phe891Leu
DDG = -0.52 Kcal/mol
Ala896Thr
DDG = -0.69 Kcal/mol
Met1718Leu
DDG = -0.25 Kcal/mol
Wild Type
Mutant
Pro105
Leu105
Val765
Gly761
Leu757
Gln764
Ala761
Arg805
Tyr811
Glu807
Lys807
Phe891
Leu891
Leu893
Ala900
Ala896
Gln892
Thr896
Met1718
Gln1728
Leu1718
Ala2054Val
DDG = -0.02 Kcal/mol
Ala3480Val
DDG = -0.11 Kcal/mol
Ser3482Ile
DDG = 0.17 Kcal/mol
Val3504Leu
DDG = -1.13 Kcal/mol
Pro3618Gln
DDG = -1.21 Kcal/mol
Gln2057
Ala2054
Val2054
Ser3482
Asp3476
Ala3480
Val3480
Glu3478
Ser3486
Ala3479
Ile3482
Glu3662
Val3504
Leu3504
Pro3618
Gln3618


A
P = 0.0043
Relative expression
1.5
1.0
0.5
0.0
Zfh2-RNAi
Zfh2 knockdown
B
Zfh2-RNAi
Zfh2 knockdown
larval length (mm)
4
3
2
1
0
1st instar
2nd instar
3rd instar
C
Seizure
Paralysis
Recovery
D
P = 0.0002
P < 0.0001
P < 0.0001
Bang-sensitive pertentage (%)
40
30
20
10
0
Canton-s
tub-Gal4
Zfh2-RNAi
Zfh2 knockdown
E
Animal recovery (%)
100
80
60
40
20
0
Zfh2 knockdown
Zfh2-RNAi
tub-Gal4
Canton-s
0
2
4
6
8
10
Time (s)


A
Antennal lobe
Projection neurons
10 µm
B
5 mV
1 s
-70 mV
WT
-70 mV
Zfh2 knockdown
C
P < 0.0001
sEPSPs Frequency (Hz)
1.0
0.8
0.6
0.4
0.2
0.0
WT
Zfh2 knockdown
D
Amplitude (mV)
1.8
1.6
1.4
1.2
1.0
0
WT
Zfh2 knockdown

A


Embryo
Larva
Pupa
Adult


Normalized mRNA level
1.5
1.0
0.5
0.0
lavae
pupae
adult day1
adult day5
adult day10

B


Mice
fetus
neonate
1 week
2 weeks
4 weeks
10 weeks
15 weeks
32 weeks
Human
fetus
neonate
infant
toddle-period
pre-school
juvenile-adult
middle-age
old-age


Normalized mRNA level
1.5
1.0
0.5
0.0
fetus
1 day
1 week
2 weeks
4 weeks
10 weeks
15 weeks
32 weeks

C


Primary motor cortex
Primary somatosensory cortex
Posteroventral (inferior) parietal cortex
Amygdaloid complex
Hippocampus (hippocampal formation)
Posterior (caudal) superior temporal cortex
Anterior cingulate (medial prefrontal) cortex
Dorsolateral prefrontal cortex
Ventrolateral prefrontal cortex
RPKM
Postconceptional years
Postconceptional year